Current and Emerging Treatments for Acid Sphingomyelinase Deficiency.

Area of Science:

• Biochemistry
• Genetics
• Lysosomal Storage Disorders

Background:

• Acid sphingomyelinase deficiency (ASMD) is an ultra-rare genetic disorder caused by SMPD1 gene variants, leading to sphingomyelin accumulation.
• Manifestations affect the liver, spleen, lungs, and bones, with potential central nervous system involvement, varying from acute (Type A) to chronic (Type B) forms.

Purpose of the Study:

• To summarize the current understanding of ASMD, including its pathophysiology, clinical spectrum, diagnosis, and therapeutic landscape.
• To highlight the recent advancements in treatment, particularly enzyme replacement therapy.

Main Methods:

• Review of existing literature on ASMD.
• Analysis of clinical data and treatment outcomes for olipudase alfa.

Main Results:

• Olipudase alfa, approved in 2022, has shown significant impact on Type B and A/B ASMD, altering the therapeutic paradigm.
• Gene therapy is under investigation as a promising approach for Type A ASMD.

Conclusions:

• ASMD diagnosis relies on biomarker measurement, enzyme activity assays, and genetic testing.
• While olipudase alfa offers a breakthrough for certain ASMD types, research continues for effective treatments for all forms, especially Type A.